Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
04/2000
04/06/2000WO1999062510A3 Compositions comprising anti-microtubule agents for treating or preventing inflammatory diseases
04/06/2000WO1999062505A3 Method for treating neurodegenerative disorders
04/06/2000WO1999061618A3 Canine and feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
04/06/2000WO1999061453A3 priA
04/06/2000WO1999061056A3 Methods and products for inducing mucosal immunity
04/06/2000WO1999061013A3 COMPOUNDS HAVING IgE AFFECTING PROPERTIES
04/06/2000WO1999059608A3 Osteoporosis treatment
04/06/2000WO1999059525A9 Broad spectrum microbicidal and spermicidal compositions, devices, and methods
04/06/2000WO1999052858A3 Lipids
04/06/2000WO1999046284A3 Molecules that home to various selected organs or tissues
04/06/2000WO1999045911A3 Universal reed-solomon coder-decoder
04/06/2000WO1999045907A3 Metal chelators for use in the treatment of alzheimer's disease
04/06/2000WO1999040906A3 Method and composition for treatment of inflammatory conditions
04/06/2000WO1999037294A3 Mitochondria protecting agents for treating mitochondria associated diseases
04/06/2000WO1999011237A9 Dermatological compositions
04/06/2000DE19845358A1 Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe Excessive dosage forms with controlled release
04/06/2000DE19845324A1 Use of nitrilotriacetic acid for stabilizing flavone, flavanone and/or flavonoid useful in cosmetic and dermatological formulations
04/06/2000DE19845322A1 Active combination based on flavone, flavanone and/or flavonoid, useful in cosmetic and dermatological formulations, contains 2-tert.-butyl hydroquinone
04/06/2000DE19845314A1 Agent for treatment of erectile dysfunction with broader effect than sildenafil, containing procyanidin compound and optionally L-arginine
04/06/2000DE19845202A1 Haarwuchsmittel Hair restorer
04/06/2000DE19845153A1 Imidazo[4,5]-pyridin-4-on-derivate Imidazo [4,5] pyridin-4-one derivatives
04/06/2000CA2774207A1 Antibiotic compositions for treatment of the eye
04/06/2000CA2714449A1 Use of certain drugs for treating nerve root injury
04/06/2000CA2659064A1 Antibiotic compositions for treatment of the ear and nose
04/06/2000CA2346061A1 Carbohydrate vaccines for viral diseases
04/06/2000CA2345988A1 Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
04/06/2000CA2345944A1 2-piperazino alkylamino benzoazole derivatives: dopamine receptor subtype specific ligands
04/06/2000CA2345672A1 Antiviral purine derivatives
04/06/2000CA2345641A1 A method for treating inflammatory diseases by administering a thrombin inhibitor
04/06/2000CA2345638A1 Oral dosage formulations comprising (2s,3s,5r) -2-(3,5- difluorophenyl) -3,5-dimethyl -2-morpholinol and an effective stabilizing amount of alginic acid
04/06/2000CA2345612A1 Anti-fungal composition
04/06/2000CA2345474A1 Oxazole compounds as prostaglandin e2 agonists or antagonists
04/06/2000CA2345462A1 Treatment of hepatitis b infection with thymosin alpha 1 in combination with lamivudine or in combination with lamivudine and famciclovir
04/06/2000CA2345359A1 Indeno-, naphto- and benzocyclohepta dihydrothiazole derivatives, the production thereof and their use as anorectic medicaments
04/06/2000CA2345357A1 Benzimidazolinyl piperidines as cgrp ligands
04/06/2000CA2345347A1 Methods for treating or preventing viral infections and associated diseases
04/06/2000CA2345273A1 Pharmaceutically active compounds and methods of use thereof
04/06/2000CA2345108A1 Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
04/06/2000CA2345066A1 Identifying agents that alter mitochondrial permeability transition pores
04/06/2000CA2345065A1 Pyrimidone derivatives
04/06/2000CA2344894A1 Agents for improving excretory potency of urinary bladder
04/06/2000CA2344873A1 2-methyl-thieno-benzodiazepine formulation
04/06/2000CA2344717A1 Adrenoleukodystrophy treatments and drug screening
04/06/2000CA2344658A1 Human kinesin-like motor protein
04/06/2000CA2344653A1 Methods of controlling proliferation and differentiation of stem and progenitor cells
04/06/2000CA2344622A1 Moraxella catarrhalis protein, nucleic acid sequence and uses thereof
04/06/2000CA2344561A1 Platelet-derived growth factor c, dna coding therefor, and uses thereof
04/06/2000CA2344050A1 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000CA2343972A1 Ykl-40 as a marker and prognostic indicator for cancers
04/06/2000CA2343939A1 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
04/06/2000CA2343811A1 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000CA2343656A1 Trex, a novel gene of traf-interacting ext gene family and diagnostic and therapeutic uses thereof
04/06/2000CA2343098A1 Combination of bisphosphonate and tetracycline
04/06/2000CA2343038A1 A novel inhibitor of cataract formation
04/06/2000CA2342981A1 Chemotherapy of cancer with acetyldinaline in combination with gemcitabine, capecitabine or cisplatin
04/06/2000CA2342622A1 New substituted indolinones,their preparation and their use as medicaments
04/06/2000CA2342603A1 Antibiotic compositions for treatment of the eye, ear and nose
04/06/2000CA2342181A1 Fermentation of clavulanic acid at a controlled level of ammonia
04/06/2000CA2341763A1 Antigenic peptides of aglyco 10b and antibodies thereto
04/06/2000CA2340454A1 Benzamide derivatives and their use as cytokine derivatives
04/06/2000CA2338442A1 Phenylalanine derivatives as alpha 4 integrin inhibitors
04/06/2000CA2311462A1 Dna encoding mammalian neuropeptide ff (npff) receptors and uses thereof
04/06/2000CA2285151A1 Novel heparin binding peptides
04/05/2000EP0990655A1 Method for drying anhydrous paroxetine hydrochloride
04/05/2000EP0990654A1 Substituted cyclobutylamine derivatives
04/05/2000EP0990650A1 Tricyclic pyrrole or pyrazole derivatives
04/05/2000EP0990442A1 Therapeutic treatment for chronic myeloid leukemia and active lymphoid leukemia
04/05/2000EP0990441A1 A drug for treating diabetic nephrosis
04/05/2000EP0990440A1 Drug composition
04/05/2000EP0990437A1 Aerosol compositions
04/05/2000EP0990041A1 Regulation of transcription in mammalian cells and viral replication by a tetracyclin repressor
04/05/2000EP0990037A2 Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
04/05/2000EP0990002A1 Dextran derivatives, preparation method and applications as medicine with specific biological action
04/05/2000EP0989993A1 Tartrate salt of a substituted dipeptide as growth hormone secretagogue
04/05/2000EP0989989A1 13-dihydro-3'aziridino anthracyclines
04/05/2000EP0989987A1 Spiro-azacyclic derivatives and their use as therapeutic agents
04/05/2000EP0989986A1 5,7-disubstituted 4-aminopyrido 2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
04/05/2000EP0989985A1 Fused polycyclic 2-aminopyrimidine derivatives as protein kinase inhibitors
04/05/2000EP0989984A1 Bispyrido-cycloheptane compounds useful for inhibition of farnesyl protein transferase
04/05/2000EP0989983A1 Benzpyrido cycloheptane compounds useful for inhibition of farnesyl protein transferase
04/05/2000EP0989982A1 Barbituric acid derivatives with antimetastatic and antitumor activity
04/05/2000EP0989981A1 Novel phenyl-substituted tricyclic inhibitors of farnesyl-protein transferase
04/05/2000EP0989980A1 Novel tricyclic sulfonamide inhibitors of farnesyl-protein transferase
04/05/2000EP0989979A1 Novel n-substituted urea inhibitors of farnesyl-protein transferase
04/05/2000EP0989978A1 Tricyclic keto amide derivatives useful as farnesyl protein transferase inhibitors
04/05/2000EP0989977A1 Carboxy piperidylacetamide tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases (farnesyl protein transferase inhibitors)
04/05/2000EP0989975A1 Oxazole compounds useful as pge2 agonists and antagonists
04/05/2000EP0989973A1 Chalcones having antiproliferative activity
04/05/2000EP0989972A1 Prostaglandin pharmaceutical compositions
04/05/2000EP0989957A1 Improved method for preparing low-concentration polyaluminosilicate microgels
04/05/2000EP0989863A2 System for the in vivo delivery and expression of heterologous genes in the bone marrow
04/05/2000EP0989862A1 Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent
04/05/2000EP0989857A1 Novel therapeutic agents that modulate enzymatic processes
04/05/2000EP0989856A1 Method and substances for releasing a growth factor from endothelial cells, growth factor released in accordance with said method and use of same
04/05/2000EP0989853A1 Self-regulated apoptosis of inflammatory cells by gene therapy
04/05/2000EP0989852A1 Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
04/05/2000EP0989851A1 Self-emulsifying formulation for acidic lipophilic compounds
04/05/2000EP0989850A1 Use of pramipexole in the treatment of restless legs syndrome
04/05/2000EP0989849A2 Therapeutic nanospheres
04/05/2000EP0989848A2 Film-coated tablet for improved upper gastrointestinal tract safety
1 ... 6338 6339 6340 6341 6342 6343 6344 6345 6346 6347 6348 6349 6350 6351 6352 6353 6354 6355 6356 6357 6358 ... 7860